AU3434601A - Compositions and methods for the treatment of immune related diseases - Google Patents

Compositions and methods for the treatment of immune related diseases

Info

Publication number
AU3434601A
AU3434601A AU34346/01A AU3434601A AU3434601A AU 3434601 A AU3434601 A AU 3434601A AU 34346/01 A AU34346/01 A AU 34346/01A AU 3434601 A AU3434601 A AU 3434601A AU 3434601 A AU3434601 A AU 3434601A
Authority
AU
Australia
Prior art keywords
compositions
treatment
methods
related diseases
immune related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34346/01A
Inventor
Sherman Fong
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Kenneth J. Hillan
Daniel Tumas
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/en
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU3434601A publication Critical patent/AU3434601A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34346/01A 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases Abandoned AU3434601A (en)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
WOUS99/28313 1999-11-30
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
US17026299P 1999-12-09 1999-12-09
US60170262 1999-12-09
US17205999P 1999-12-23 1999-12-23
US60172059 1999-12-23
US17548100P 2000-01-11 2000-01-11
US60175481 2000-01-11
US17711800P 2000-01-20 2000-01-20
US60177118 2000-01-20
WOUS00/04342 2000-02-18
PCT/US2000/004342 WO2000078961A1 (en) 1999-06-23 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US18720200P 2000-03-03 2000-03-03
US60187202 2000-03-03
WOUS00/14941 2000-05-30
PCT/US2000/014941 WO2000073348A2 (en) 1999-06-02 2000-05-30 Methods and compositions for inhibiting neoplastic cell growth
US20983200P 2000-06-05 2000-06-05
US60209832 2000-06-05
WOUS00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US60000000 2000-09-15
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
AU3434601A true AU3434601A (en) 2001-06-12

Family

ID=27558595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34346/01A Abandoned AU3434601A (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases

Country Status (5)

Country Link
EP (1) EP1234036A2 (en)
JP (4) JP4211966B2 (en)
AU (1) AU3434601A (en)
CA (1) CA2390786A1 (en)
WO (1) WO2001040465A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503730B1 (en) 1997-06-19 2003-01-07 Schering Corporation Nucleic acids encoding a cysteine rich protein
US7365157B2 (en) * 1999-12-23 2008-04-29 Genentech, Inc. PRO9912 polypeptides
EP1897945B1 (en) * 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030153015A1 (en) 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1463525B1 (en) * 2001-12-19 2008-09-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2518101A1 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
CA2550117A1 (en) * 2003-12-16 2005-06-30 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
KR20110025649A (en) 2008-05-05 2011-03-10 노비뮨 에스 에이 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
RU2605318C2 (en) 2009-05-05 2016-12-20 Новиммун С.А. Anti-il-17f antibodies and methods for use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5874230A (en) * 1996-07-10 1999-02-23 Tularik, Inc. Assays using TRAF2-associated protein kinase polypeptides
AU4268097A (en) * 1996-09-12 1998-04-02 Human Genome Sciences, Inc. Chemokine alpha-4
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
WO1998045436A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1998058061A1 (en) * 1997-06-19 1998-12-23 Schering Corporation Mammalian genes; related reagents
WO1999038959A1 (en) * 1998-01-30 1999-08-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
IL139219A0 (en) * 1998-04-24 2001-11-25 Genentech Inc Fizz proteins

Also Published As

Publication number Publication date
JP4226605B2 (en) 2009-02-18
EP1234036A2 (en) 2002-08-28
JP4242371B2 (en) 2009-03-25
WO2001040465A3 (en) 2002-03-21
WO2001040465A2 (en) 2001-06-07
CA2390786A1 (en) 2001-06-07
JP2006197937A (en) 2006-08-03
JP2006068007A (en) 2006-03-16
JP4211966B2 (en) 2009-01-21
JP2003530082A (en) 2003-10-14
JP2008301810A (en) 2008-12-18

Similar Documents

Publication Publication Date Title
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
IL145470A0 (en) Compositions for the treatment of immune diseases
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2495200A (en) Compositions and methods for the treatment of tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
EP1472273A4 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase